Khondrion was founded by Prof. Dr. Jan Smeitink, a world-leader in mitochondrial medicine. He has devoted his entire career to the care of mitochondrial disease patients, to better understand the complexity of this disease and his life mission is to develop a treatment for these high impacts, often early fatal group of disorders. Fully operational since 2012 and located in Nijmegen, The Netherlands, Khondrion primarily focuses on the development of innovative therapies for inherited mitochondrial diseases, including Leigh Disease, MELAS, Leber’s Hereditary Optic Neuropathy and other Respiratory Chain / Oxidative Phosphorylation disorders.

Our company's focus is on our own product development programmes. We have extensive experience in mitochondrial medicine, unique quantitative live-cell imaging technologies and in-depth characterised patients-derived cell panels. In this scope, we have developed a portfolio of pre-clinical drug candidates, among them the frontrunner KH176 is currently under clinical evaluation.


Bedrijfsnaam: Khondrion
Organisatietype: Bedrijf
Specialisatie: Biotechnologie, Farma, Research & Development
Bezoekadres: Transistorweg 5C, 6534 AT, Nijmegen, Nederland
Postadres: Postbus 9101, 6500 HB, Nijmegen, Nederland
KvK: 9169454


Publicatiedatum: januari 13, 2021

Khondrion announces publication in Scientific Reports

Publicatiedatum: augustus 01, 2018

9 miljoen voor 5 Nederlandse innovatieve scale-ups

Publicatiedatum: november 16, 2017

Khondrion will present first results of KHENERGY study

Making the difference by unlocking new value

Is dit bedrijf voor jou een potentiële match? Neem dan contact op met:

Mirjam van den Bosch
Innovatiemanager Health Valley Netherlands

Mirjan van den Bosch

Health Valley Partners